Abstract Chronic kidney disease (CKD) has reached worldwide epidemic proportions and desperately needs new therapies. Peritubular capillary (PTC) rarefaction, together with interstitial fibrosis and tubular atrophy, is one of the major hallmarks of CKD and predicts renal outcome in patients with CKD. PTC endothelial cells (ECs) undergo apoptosis during CKD, leading to capillary loss, tissue hypoxia, and oxidative stress. Although the mechanisms of PTC rarefaction are not well understood, the process of PTC rarefaction depends on multiple events that occur during CKD. These events, which lead to an antiangiogenic environment, include deprivation of EC survival factors, increased production of vascular growth inhibitors, malfunction of ECs, dysfunction of endothelial progenitor cells, and loss of EC integrity via pericyte detachment from the vasculature. In this review, we focus on major factors regulating angiogenesis and EC survival and describe the roles of these factors in PTC rarefaction during CKD and possible therapeutic applications.
Introduction
Chronic kidney disease (CKD) affects one in every seven adults in the USA, with a worldwide prevalence that is reported to range from 10 to 13 %. CKD is a leading cause of death due to premature cardiovascular diseases [1] [2] [3] . While a variety of conditions can lead to CKD, the final common pathway of renal destruction involves interstitial fibrosis, tubular atrophy, and peritubular capillary (PTC) rarefaction. Despite numerous published studies that have investigated the mechanisms of renal fibrosis, the mechanisms of PTC rarefaction remain incompletely understood. Therefore, in this review we focus on PTC rarefaction. The results of several studies in human CKD and animal models of CKD have demonstrated that PTCs disappear in association with progressive interstitial fibrosis and tubular atrophy. Although the sequence of events connecting PTC loss to fibrosis and impaired tubular function is poorly characterized, it has been suggested that interstitial hypoxia due to arteriolar vasoconstriction and/or PTC regression is a primary event in CKD [4] . In this review, we describe (1) the contribution of PTC rarefaction to CKD progression, (2) the mechanisms of PTC rarefaction, (3) major factors regulating endothelial cell (EC) survival and angiogenesis in CKD, and (4) putative therapeutic targets for PTC rarefaction.
Contribution of PTC rarefaction to CKD progression
Loss of renal PTCs is correlated with the severity of fibrosis in human patients during CKD [5] [6] [7] and chronic allograft rejection [8] . The extent of PTC loss has been found to predict both interstitial damage and glomerular filtration rate (GFR) in human subjects [6] . Rodent CKD models, such as experimental glomerulonephritis [9] , the remnant kidney model [10] , unilateral ureteral obstruction (UUO, obstructive nephropathy model) [11] [12] [13] [14] , and the aging kidney [15] , have also shown a negative correlation between capillary density and the severity of fibrosis (Fig. 1) . Furthermore, damage to PTCs has been found to influence the long-term outcome after ischemia-reperfusion injury (IRI) [16] . In this study with treated rats, the GFR returned to the normal range 1-2 weeks after bilateral IRI; however, over 40 weeks, the animals developed prominent fibrosis, which was accompanied by a 30-50 % reduction in PTC density [16] . Similar results have been obtained in mice [17] . These experimental results are similar to outcomes of clinical studies in which acute kidney injury dramatically increased the risk of developing endstage renal disease [18, 19] . Taken together, these findings strongly suggest that PTC rarefaction contributes to the progression of CKD. It is currently speculated that PTC rarefaction is both a cause and a result of CKD progression.
Mechanisms of PTC rarefaction
In healthy kidneys, there is a tightly controlled balance between the expression of proangiogenic and antiangiogenic molecules. However, this balance is disrupted in CKD, leading to an antiangiogenic environment that favors the loss of PTCs (Fig. 2) .
Angiogenesis has been investigated in several models of CKD [10, 11, 20, 21] . In the rat UUO model, Ohashi et al. [11] observed early angiogenesis (EC proliferation) in PTCs, accompanied by intense expression of vascular endothelial growth factor (VEGF), a major proangiogenic factor, within the tubular epithelium. This was followed by EC apoptosis in PTCs, a decrease in VEGF and its major angiogenic receptor VEGF receptor 2 (VEGFR-2), and capillary regression. Vascular growth inhibitors may also modulate angiogenesis and tissue damage during chronic injury [22] . Thrombospondin-1 (TSP-1) was found to be up-regulated in the rat remnant kidney at the time when early EC proliferation declined [10] . In the mouse UUO and IRI models, endostatin, another antiangiogenic factor, was elevated after kidney injury [23, 24] (Table 1) .
In response to kidney injury, ECs of PTCs may initially proliferate and subsequently disappear due to apoptosis. Endothelial apoptosis is induced by deprivation of Fig. 1 Immunofluorescence staining for CD31 (green) to visualize peritubular capillaries (PTCs) in the mouse kidney cortex. Left Control, Right day 7 after unilateral ureteral obstruction (UUO) surgery. Note that the CD31+ PTC density is profoundly reduced in the UUO kidney compared with the control kidney. g Glomerulus. Bar: 50 μm Fig. 2 Schematic of mechanisms of peritubular capillaries (PTC) rarefaction following kidney injury. a In the healthy kidney, pericytes (PC) are embedded into the capillary basement membrane (BSM) and attached to capillary endothelial cells (EC). This close relationship between PCs and ECs supports capillary integrity. b Subsequent to an initial insult, angiogenic factors (e.g. vascular endothelial growth factor) are up-regulated and ECs are proliferative. PCs promptly start to migrate away from the capillary area. Simultaneously, inflammatory cells infiltrate into the interstitium. c In response to continuous insults (1) angiogenic factors are down-regulated, (2) anti-angiogenic factors (e.g., thrombospondin-1) are up-regulated, (3) endothelial progenitor cells (EPCs) do not promote neoangiogenesis, (4) PC detachment from vasculature destabilizes ECs, and EC (5) dysfunction and EC apoptosis progress. All of these mechanisms contribute to an antiangiogenic environment, resulting in PTC rarefaction. The capillary BSM is also degraded. Additionally, a large number of inflammatory cells migrate from the capillary lumen into the extracapillary space. Note that some of the angiogenic factors (e.g., angiopoietin-1) and antiangiogenic factors (e.g., thrombospondin-1) induce the infiltration of inflammatory cells, which in turn impairs the angiogenic response survival growth factors, such as VEGF, and by increased proapoptotic stimuli, such as FasL, interleukin-1, and tumor necrosis factor α (TNF-α) [25, 26] . Apoptotic ECs become pro-coagulant and pro-adhesive, leading to capillary occlusion by thrombosis and enhanced inflammation by extravasation of leukocytes. Impairment of blood flow decreases laminar shear stress on ECs, resulting in further endothelial apoptosis [27] . Furthermore, following kidney injury, vascular pericytes, which structurally and functionally stabilize PTC ECs, promptly migrate away and differentiate into myofibroblasts [28] . In the absence of pericytes, PTCs are destabilized, resulting in further PTC loss [28] .
It has been reported that PTC density is positively correlated with proximal tubular density in patients with CKD [5] . Renal tubular epithelial cells make up the bulk of the renal mass, and these cells disappear during the progression of CKD. Without any additional insults, genetic ablation of proximal tubules causes PTC loss and fibrosis in vivo [29] . However, how the reduction of tubular mass induces PTC loss is still poorly understood.
Major factors regulating angiogenesis and EC survival in CKD
Vascular endothelial growth factor Despite its complexity, angiogenesis is predominantly regulated by a single growth factor, VEGF-A [30] . VEGF-A is expressed in podocytes and renal tubular epithelial cells in the developing kidneys and continues to be expressed in the adult kidneys. VEGFR-1 (Flt1) and VEGFR-2 (Flk1/KDR) are expressed predominantly in ECs. VEGFR-1 is thought to act as a decoy receptor that sequesters VEGF-A from VEGFR-2 binding. In a recent genome-wide association study, VEGF-A was identified as a risk locus related to CKD [31] , indicating that VEGF-A has a pivotal role in the development of CKD. The dose-dependent deletion or overexpression of VEGF-A in podocytes leads to a variety of glomerular capillary diseases, including mesangiolysis and endotheliosis, suggesting that VEGF-A is an essential growth factor for the development and maintenance of glomerular capillaries [32] [33] [34] . VEGF-A has also been found to CKD, Chronic kidney disease; ADAMTS-1, a disintegrin and metalloproteinase with thrombospondin motif-1; EC, endothelial cell; PC, pericyte; PlGF, placental growth factor; VEGF, vascular endothelial growth factor; VEGFR-2, VEGF receptor-2 be important for tubular development [35] . Burt et al. found that VEGF expression continuously increased in tubular epithelial cells in neonatal rats between 14 and 28 days after birth, but was reduced after UUO [36] . In this study, VEGFR-2 was expressed strongly in the microvasculature in neonatal kidneys in both sham and UUO groups, whereas in adult rat kidneys VEGFR-2 expression was low in sham operated kidneys but increased after UUO [36] . These results suggest that the vascular response to kidney injury differs between developing kidneys and mature kidneys. In human kidney biopsies, VEGF was dominantly expressed in podocytes in normal adult kidneys; however, a marked increase of VEGF expression in the renal tubules was observed in CKD [5] .
Angiopoietins
Angiopoietins are another critical family of angiogenic factors that play a significant role in renal vascular development as well as renal vascular homeostasis. Angiopoietin-1 (Ang-1), angiopoietin-2 (Ang-2), and the receptor tyrosine kinases Tie-2 (also known as TEK) and Tie-1 (a homolog to Tie-2 about which relatively little is known) are all highly expressed in developing kidneys. Their expression peaks at birth, and they continue to be expressed in the mature kidneys. In the adult kidney, Ang-1 is expressed in tubular epithelial cells, podocytes, and pericytes, whereas Ang-2 is detected in ECs, with lower levels in tubular epithelial cells. Tie-2 is expressed in glomerular and peritubular ECs in addition to hematopoietic cells [37] [38] [39] . In general, Ang-1 binds to Tie-2, enhancing EC survival, reducing vascular permeability, and stabilizing capillaries, whereas Ang-2 competitively inhibits the binding of Ang-1 to Tie-2. The biological effects of Ang/Tie signaling may depend on an interaction with VEGF. It was demonstrated in the eye that Ang-2 induced angiogenesis in the presence of VEGF, but led to vascular regression in the absence of VEGF [40] . Recent studies suggest that Ang-1 and Ang-2 can affect the inflammatory process [38] . It is possible that Ang-1 and Ang-2 affect leukocyte transmigration stimulated by TNF-α [41] . In one study in mice, overexpression of Ang-2 in podocytes produced a phenotype similar to diabetic nephropathy, where glomerular endothelial apoptosis is prominent [42] . Ang-2 is also strongly expressed in tubules surrounding mature vasa recta, which express Tie-2 [43] , suggesting that Ang/Tie-2 signaling contributes to the maintenance of vasa recta. In a study in patients with CKD, the serum level of Ang-1 was decreased and that of Ang-2 was elevated [44] , generating an antiangiogenic environment. The renal Ang-1 level is also decreased in the UUO model [45] . In contrast, other renal injury models (folic acid nephropathy, IRI, and angiotensin II infusion) have shown increased Ang-1 expression in the kidneys [44] .
This difference in Ang-1 expression indicates a unique profile in each animal model of CKD. Studies using inducible Ang-1 deletion after mouse embryonic day 13.5 (E13.5) produced no immediate vascular phenotype in healthy kidneys [46] . However, Ang-1 deficiency after E13.5 resulted in profound renal damage, including affected vasculature after kidney insult, indicating a protective role of Ang-1 in kidney injury [46] .
Fibroblast growth factor-2
Fibroblast growth factor-2 (FGF-2) is another potent angiogenic growth factor, which binds to four high-affinity FGF receptors (FGFR-1, 2, 3, and 4). In the normal human kidney, FGF-2 is expressed in glomerular parietal cells, podocytes, distal tubular epithelial cells, ECs, and vascular smooth muscle cells [47] . In mouse cornea, FGF-2 stimulates VEGF-A expression in ECs and stromal cells, which is required for its angiogenic activity [48] . Furthermore, ECs lacking FGF signaling were found to be unresponsive to VEGF-A, because disruption of FGF signaling down-regulated VEGFR2 expression [49] . These results indicate that FGF signaling and VEGF signaling work together for angiogenesis. Blocking FGF signaling in mice using an adenovirus encoding soluble FGFR resulted in the loss of arteriogenic response and vascular integrity [49, 50] . Although FGF-2 expression has been reported to correlate with the degree of interstitial fibrosis in human kidney samples [51] , the role of FGF-2 in PTC rarefaction has not been investigated.
Nitric oxide and endothelial nitric oxide synthase
Nitric oxide (NO) is synthesized from L-arginine by endothelial nitric oxide synthase (eNOS) and functions to maintain ECs in a quiescent state, as opposed to a stressed/damaged ("activated") state that promotes vasoconstriction as well as coagulation and inflammation ("endothelial activation"). A reduced availability of NO and concurrent endothelial dysfunction have been documented in patients with CKD [52] . Moreover, circulating levels of asymmetric dimethylarginine (ADMA), an endogenous NOS inhibitor, have been found to be elevated in CKD patients [53] . Recently, ADMA accumulation was found to reduce eNOS phosphorylation and inhibit eNOS activity in the remnant kidney model of CKD [54] . One recent study showed that the administration of L-arginine increased NO synthesis, eNOS expression, and PTC density, and attenuated fibrosis in the rat UUO model, while PTC loss and fibrosis were more severe after treatment with the NOS inhibitor N-nitro-L-arginine methyl ester [55] . In another study using the remnant kidney model, eNOS-deficient mice showed accelerated PTC rarefaction due to decreased EC proliferation and increased EC apoptosis, accompanied by enhanced macrophage infiltration and fibrosis [56] . These results suggest that NO protects against PTC rarefaction in CKD.
Nitric oxide is also involved in the renoprotective effects of angiotensin converting enzyme (ACE) inhibitors in CKD. Angiotensin II uncouples the eNOS-catalyzed consumption of NADPH from the oxidation of L-arginine, leading to the production of superoxide (harmful for ECs) rather than NO (beneficial to ECs) [57] . Therefore, treatment of CKD patients with ACE inhibitors or angiotensin receptor blockers can shift the balance back toward NO production and reduce endothelial activation; this action is independent of the blood pressure-lowering effect of these agents.
Hypoxia-inducible factor
One of the most obvious consequences of PTC rarefaction is a decreased oxygen supply to the tubulointerstitial tubulointerstitial compartment. Various response pathways are activated during hypoxia in the kidney. On the molecular level, the most important adaptations to hypoxia are mediated by hypoxia-inducible factor (HIF). Mammalian HIFs function as heterodimeric transcription factors composed of either HIF-1α or HIF-2α bound to HIF-1β (also known as aryl hydrocarbon nuclear translocator) [58] . In the hypoxic kidney, HIF-1α is expressed in tubular and glomerular epithelial cells, whereas HIF-2α is detected in glomerular and peritubular ECs and fibroblasts [59] . The primary mechanism of regulating HIF activity is oxygen-dependent proteasomal degradation of the α subunit. In normoxia, the α subunit is rapidly subjected to prolyl hydroxylation, binds to the von Hippel-Lindau tumor suppressor protein, and undergoes proteasomal degradation. In hypoxia, however, the α subunit escapes prolyl hydroxylation and binds to the β subunit. The functional heterodimeric HIF then translocates to the nucleus and promotes angiogenesis, erythropoiesis, and energy metabolism [58] .
Increased HIF expression has been reported in kidney biopsies of patients with diabetic nephropathy, immunoglobulin A nephropathy, polycystic kidney disease, and chronic allograft nephropathy [4] . However, the role of increased HIF in CKD is controversial. Several studies using genetically altered mice have demonstrated that HIF-1α expression promotes kidney fibrosis in the UUO model [60] and the remnant kidney [61] . In agreement with these results, one clinical study confirmed a negative effect of HIF-1α activation on renal and patient survival in patients with acute kidney injury [62] . In contrast, the activation of HIFs appears to play a protective role in interstitial fibrosis and preserves PTC area in various different experimental renal diseases (the remnant kidney, IRI, cisplatin nephropathy, and diabetic nephropathy) [63] [64] [65] . Although HIF-1α null or HIF-2α null ECs constitute dysfunctional vasculature in other organs [66, 67] , no study has been performed to investigate the role of HIF-1α or HIF-2α specifically in kidney ECs during CKD. For the regeneration of PTCs in CKD, strategies involving HIF need to be directed to specific cell types in the kidney to avoid adverse effects.
Other factors
Several other factors have been reported to affect angiogenesis following kidney injury. Thrombospondin-1 (TSP-1) is a 450-kDa homotrimeric extracellular matrix protein and a potent anti-angiogenic factor. TSP-1 expression in the normal kidney is limited to Bowman's capsule, whereas in the damaged kidney TSP-1 is expressed in all glomerular cell types as well as in tubular epithelial cells, myofibroblasts, and infiltrating macrophages [68] . In UUO model study, TSP-1 null mice displayed less inflammation and had better PTC preservation than wild-type controls [68] , indicating that TSP-1 has a deleterious role in PTC rarefaction during CKD. However, in another study TSP-1-deficient ECs exhibited decreased phosphorylation of VEGFR-2 in response to VEGF-A stimulation compared with wild-type ECs [69] . This result suggests that TSP-1 promotes the inflammatory response and inhibits angiogenesis via its pro-inflammatory activity rather than via impairment of VEGF signaling after kidney injury. Although previous studies reported that TSP-1 enhanced apoptosis of ECs [70] and inhibited EC responses to NO [71] , the mechanisms by which TSP-1 inhibits angiogenesis in CKD are still not clear.
CD44 is a glycoprotein that binds to hyaluronic acid (HA). In one study, CD44 expression was increased in ECs located in PTCs following UUO treatment, and CD44-deficient mice preserved more PTC area than wild-type mice and showed decreased endothelial apoptosis [12] . In this same study, an interaction between CD44 and HA enhanced the pro-apoptotic effect of transforming growth factor-β1 on ECs [12] .
ADAMTS-1 (a disintegrin and metalloproteinase with thrombospondin motif-1), a secreted VEGF inhibitor, appears to be an antiangiogenic factor [72] and destabilizes vessels after IRI [73] .
In addition to VEGF-A and FGF-2, hepatocyte growth factor (HGF) has been shown to function as an angiogenic factor through binding to its receptor, c-Met [74] . In the remnant kidney model, infusion of HGF was found to remarkably ameliorate macrophage adhesion to ECs, whereas neutralizing endogenous HGF worsened macrophage adhesion [75, 76] . These results suggest that HGF may preserve PTCs through an anti-inflammatory action.
Considerations for therapy to limit PTC rarefaction in CKD

Treatment with angiogenic growth factors
Multiple studies have demonstrated that VEGF-A may help to preserve PTCs in CKD. In the remnant kidney model, administration of recombinant VEGF-A 121 improved renal function, lowered mortality, decreased PTC rarefaction, and reduced fibrosis [77] . Similarly, in a pig model of renal artery stenosis, intrarenal infusion of VEGF-A attenuated microvascular rarefaction, prevented fibrosis, and improved renal blood flow [78] . However, other results did not support the beneficial effects of VEGF-A in CKD. In an experimental model of kidney injury induced by angiotensin II infusion followed by a high-salt diet, the administration of VEGF-A 121 did not improve PTC rarefaction [79] . In addition, VEGF-A 121 treatment did not improve PTC rarefaction in neonatal mouse kidneys subjected to UUO [80] , and systemic overexpression of a mutant form of VEGF-A that can bind only to VEGFR-2 but not to VEGFR-1 enhanced glomerular injury as well as interstitial fibrosis in mice with uninephrectomy [81] . Furthermore, the timing of angiogenic treatment is crucial. In the rat remnant kidney model, VEGF-A 121 delivered 4-8 weeks after surgery ameliorated CKD, perhaps because VEGF-A levels in the kidney are very low during this period and PTC rarefaction is severe [77] . By contrast, the first 4 weeks after surgery in the remnant kidney model were characterized by glomerular hypertrophy and increased VEGF-A levels [82] . During this initial period, neutralizing VEGF-A, but not VEGF-A injection, was able to improve renal function and glomerular hypertrophy [82] . In contrast, secondary CKD induced by a salt-rich diet following recovery from IRI was ameliorated by VEGF-A 121 only when it was injected immediately (within 3 days) after IRI [83] . These discrepancies in the effect of VEGF-A on CKD raise important considerations for future therapeutic strategies that target angiogenesis in CKD.
A soluble, stable, and more potent form of Ang-1 (COMP-Ang-1) was successfully used in the mouse UUO and IRI models to preserve PTC area and renal blood flow and to decrease inflammation and fibrosis [45, 84] , suggesting the possible use of Ang-1 as a novel treatment for patients with CKD. However, Long et al. reported contradictory findings [38] . In mice with folic acid-induced kidney injury, these authors systemically delivered a recombinant form of Ang-1 (Ang-1*) using adenoviruses, which improved PTC rarefaction but enhanced inflammation and fibrosis [38] . Further studies are necessary to reveal the relationship between angiogenesis and inflammation in CKD. Combination therapy with VEGF-A and Ang-1 could potentially overcome this problem, as Ang-1 stabilizes blood vessels and prevents VEGF-induced endothelial leakiness [85] .
Finally, there is one caveat against the inhibition of VEGF signaling. As reported in clinical settings such as cancer therapy, blockade of VEGF signaling causes proteinuria, hypertension, and renal thrombotic microangiopathy due to disruption of the glomerular filtration barrier [86, 87] .
Endothelial progenitor cells
Endothelial progenitor cells (EPCs) have been suggested to be useful for maintaining the integrity of ECs and for repairing ECs after injury [88] . EPCs are identified by a consensus combination of markers and characteristics (individually not unique to EPCs) that include CD34, VEGFR-2, Tie-2, CD133, Ulex Europeus lectin binding, uptake of acetylated low-density lipoprotein, and the ability to form colonies (colony-forming units) [88] . Chade et al. demonstrated that intra-renal infusion of autologous EPCs attenuated PTC rarefaction and fibrosis, improving renal function by stimulating angiogenesis [89] . The adoptive transfer of EPCs could be one option to promote de novo angiogenesis and renal regeneration.
One may wonder why resident EPCs are insufficient to trigger neo-angiogenesis after kidney injury. This deficiency may arise from disease-related changes in EPC function. Zhu et al. observed that EPCs taken from pigs with unilateral renal artery stenosis in the early and later phases of disease progression had different characteristics [90] . In this study, EPCs isolated from peripheral blood in the early phase exhibited increased proliferation, tube formation, VEGF-A and eNOS expression, and augmented expression of C-X-C chemokine receptor type 4 (CXCR4) [90] . The homing of EPCs expressing CXCR4 is regulated by the ligand of CXCR4, α-chemokine stromal cell-derived factor 1 (SDF-1) [91] . However, in the study of Zhu et al. [90] , these enhanced functions were not maintained in the EPCs isolated in the later phase of this disease. In another study, EPCs from patients with CKD displayed functional impairments (i.e., hampered adherence, reduced endothelial outgrowth potential, and reduced anti-thrombotic function) [92] , which became more apparent when CKD progressed [92] . These results provide evidence that endogenous EPCs become dysfunctional as CKD advances, leading to an impairment of the repair process by endogenous EPCs. One way to overcome this deficiency is the adoptive transfer of exogenous EPCs isolated from healthy donors. It should be noted that the role of EPCs in endothelial repair remains controversial. Although EPCs are able to form vascular structures, these may not be stable. Alternatively, EPCs may orchestrate angiogenic processes, while proliferation of existing ECs is quantitatively more significant for vessel formation or repair following kidney injury [93, 94] .
Endothelial-pericyte interactions
Interactions between ECs and intimately associated pericytes have recently been demonstrated to be important to preserve PTCs and to alleviate fibrosis [28, 95] . Endothelial-pericyte cross-talk has been shown to be critical for angiogenesis and vascular stabilization and to involve multiple ligand/receptor interactions, including plateletderived growth factor (PDGF)-B/PDGF receptor-β (PDGFRβ) and Ang-1/Tie-2 [96] . In this study, PDGF-B/PDGFRβ signaling was found to be essential for the recruitment of pericytes to vasculature, and ECs were not integrated properly into vessels without this signaling, leading to endothelial hyperplasia, abnormal EC junctions, microaneurysms, hemorrhages, and capillary rarefaction [96] . In another study, endothelial-pericyte interactions were disrupted in IRI and UUO models of CKD, and pericytes detached and migrated away from the microvasculature, ultimately differentiating into myofibroblasts [95] . When either PDGFRβ signaling in pericytes or VEGFR-2 signaling in ECs was blocked by circulating soluble receptor ectodomains, both PTC rarefaction and fibrosis were markedly attenuated during CKD progression [95] . The important findings of this study are that (1) bidirectional signaling between pericytes and ECs was necessary to prevent pericyte detachment from vessels, and (2) pericyte detachment was responsible for both PTC rarefaction and fibrosis. Thus, targeting the cross-talk between these two types of cells may provide a novel therapeutic opportunity to treat PTC rarefaction and fibrosis in CKD.
In the clinical setting, Richeldi et al. treated patients with idiopathic pulmonary fibrosis (IPF) for 1 year with BIBF 1120, a triple angiokinase inhibitor that can block signaling by multiple tyrosine kinase receptors, including PDGFRβ and VEGFR-2 [97] . Among these patients, BIBF 1120 significantly prevented exacerbation of IPF, suggesting a beneficial effect of the drug on organofibrosis. The most frequent adverse effect of the drug was gastrointestinal issues, such as diarrhea and vomiting, although no information was provided by these authors on capillary density in any organ [97] .
The concept of pericyte detachment suggests a connection between PTC rarefaction and kidney fibrosis. Zeisberg et al. also suggested another concept of endothelial-tomesenchymal transition (EndMT) based on studies of fatemapped ECs using Tie2-Cre;Rosa26 Reporter-stop-EYFP bigenic mice [98] . Further studies are required to evaluate the roles of pericytes as well as EndMT in capillary rarefaction in CKD.
Conclusion
The collective data from both clinical and experimental studies support the concept that PTC rarefaction is not only a prominent histological characteristic of CKD but also a central driving force that contributes to the progression of CKD. As multiple factors contribute to PTC rarefaction in each phase of the disease process, the treating physician needs to tailor the treatment according to the stage of CKD.
